Takeda Pharmaceutical is scheduled to report second-quarter results on Thursday. Here's what you need to know:
NET PROFIT FORECAST: Takeda is expected to post net profit of 67.8 billion yen, equivalent to $429.2 million, for the three months ended September, according to a poll of analysts by Visible Alpha. The drugmaker booked a net loss of Y11.8 billion in the year-earlier period.
REVENUE FORECAST: Revenue is estimated to have risen 3.6% to Y1.153 trillion, according to the Visible Alpha poll.
The stock has risen 30% year to date, compared with a 27% gain in the Nikkei Stock Average.
WHAT TO WATCH:
--For the fiscal year ending March 2027, the company has projected a 3.0% rise in revenue to Y4.640 trillion and net profit of Y166.00 billion, compared with a net loss the previous year. Investors will be focusing on changes to annual guidance as well as any impact on its operations from higher energy prices and interest rates.
--First-quarter sales of ulcerative colitis drug Entyvio climbed 15% to Y268.3 billion, while sales of plasma-derived products rose 8.8% to Y283.9 billion. Investors will be closely watching for sales momentum of key products.
--The company's operating profit margin was 16.5% in its first quarter, compared with 16.7% in the year-earlier period. Investors will be paying attention to margin trends as businesses are dealing with relatively high inflation in many parts of the world.
Comments